Decrease in CD226 expression on CD4+ T cells in patients with endometriosis

Cui Li, Jing Zhou, Jun Shao, Lei Yuan, Qiang Cheng, Ling Wang, Zhongliang Duan
Bioscience trends · 2023 · vol. 17(2) , pp. 168–171 · doi:10.5582/bst.2022.01501 · PMID:37081668 · W4366504091
article OA: diamond CC0 ⤵ 3 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Endometriosis patients exhibit reduced CD226 expression on CD4+ T cells, which correlates with effector function, and blocking CD226 suppresses this function.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 · read from full text ⓘ

The correspondence studied proportions and effector-function markers of immune-checkpoint molecules CD226 and TIGIT on peripheral CD4+ T cells in patients with endometriosis versus controls, with comparisons of associated cytokines and HLA-DR expression. It found no significant difference in TIGIT percentage on CD4+ T cells, but CD226 expression was significantly lower in endometriosis (P < 0.01). TNF-α, IL-10, and IFN-γ were elevated in both TIGIT+ and CD226+ CD4+ T-cell subsets relative to their negative subsets, and HLA-DR+ cells were more numerous in TIGIT+ and CD226+ subsets; blocking TIGIT increased IL-10 in TIGIT+ cells, while blocking CD226 reduced TNF-α and IFN-γ and increased IL-10. This study directly reports altered CD226 on CD4+ T cells in endometriosis, linking diminished CD226 expression to changes in CD4+ T-cell function.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a chronic inflammatory disease. The immune-checkpoint molecules CD226 and TIGIT play an important role in regulating T cells' function. However, little is known about the proportion and function of CD226 and TIGIT on CD4+ T cells in endometriosis. The current study found no significant differences in the TIGIT percentage on peripheral CD4+ T cells between patients with endometriosis and the control group. However, CD226 was lower in patients with endometriosis than that in the control group (P < 0.01). The cytokines TNF-α, IL10, and IFN-γ were significantly elevated in TIGIT+ CD4+ T cells compared to TIGIT- CD4+ T cells. HLA-DR+ cells were more numerous among TIGIT+ CD4+ T cells than among the TIGIT- subset (P <0.001). Similarly, the cytokines TNF-α, IL10, and IFN-γ were significantly elevated in CD226+ CD4+ T cells compared to levels in CD226- CD4+ T cells. The proportion of HLA-DR+ CD4+ T cells among CD226+ CD4+ T cells was also significantly higher than that among the CD226- subset (P < 0.001). After TIGIT was blocked, the level of IL-10 in TIGIT+ CD4+ T cells was higher than that in cells with unblocked TIGIT. There were no differences in TNF-α and IFN-γ. After CD226 was blocked, TNF-α and IFN-γwere lower while IL-10 was higher. In conclusion, there is a diminution of CD226 in CD4+ T cells in patients with endometriosis. This is correlated with the effector function of CD4+ T cells, and blocking CD226 can suppress this function.
Full text 1,757 characters · extracted from oa-doi-fallback · click to expand
Correspondence Decrease in CD226 expression on CD4+ T cells in patients with endometriosis 2023 Volume 17 Issue 2 Pages 168-171 Details Abstract Endometriosis is a chronic inflammatory disease. The immune-checkpoint molecules CD226 and TIGIT play an important role in regulating T cells' function. However, little is known about the proportion and function of CD226 and TIGIT on CD4+ T cells in endometriosis. The current study found no significant differences in the TIGIT percentage on peripheral CD4+ T cells between patients with endometriosis and the control group. However, CD226 was lower in patients with endometriosis than that in the control group (P < 0.01). The cytokines TNF-α, IL10, and IFN-γ were significantly elevated in TIGIT+ CD4+ T cells compared to TIGIT- CD4+ T cells. HLA-DR+ cells were more numerous among TIGIT+ CD4+ T cells than among the TIGIT- subset (P <0.001). Similarly, the cytokines TNF-α, IL10, and IFN-γ were significantly elevated in CD226+ CD4+ T cells compared to levels in CD226- CD4+ T cells. The proportion of HLA-DR+ CD4+ T cells among CD226+ CD4+ T cells was also significantly higher than that among the CD226- subset (P < 0.001). After TIGIT was blocked, the level of IL-10 in TIGIT+ CD4+ T cells was higher than that in cells with unblocked TIGIT. There were no differences in TNF-α and IFN-γ. After CD226 was blocked, TNF-α and IFN-γwere lower while IL-10 was higher. In conclusion, there is a diminution of CD226 in CD4+ T cells in patients with endometriosis. This is correlated with the effector function of CD4+ T cells, and blocking CD226 can suppress this function. © 2023 International Research and Cooperation Association for Bio & Socio-Sciences Advancement Favorites & Alerts Recently viewed articles

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Interleukin-10 Interleukin-10 Interleukin-10

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (3)

References (14)

Cited by (3)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-06-04T00:33:56.134770+00:00
License: CC0 · commercial use OK